Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Six analysts have provided mixed ratings for Vir Biotechnology (NASDAQ:VIR) in the latest quarter. The average 12-month price target is $65.33, with a high of $110.00 and a low of $15.00. Recent analyst actions include rating upgrades and maintained ratings, reflecting evolving sentiments.
August 02, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Six analysts have provided mixed ratings for Vir Biotechnology (NASDAQ:VIR) in the latest quarter. The average 12-month price target is $65.33, with a high of $110.00 and a low of $15.00. Recent analyst actions include rating upgrades and maintained ratings, reflecting evolving sentiments.
The mixed ratings and recent upgrades suggest a positive short-term outlook for Vir Biotechnology. The average price target has increased slightly, indicating analyst confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100